%0 Journal Article %1 oster_menzb:_2005 %A Oster, Philipp %A Lennon, Diana %A O'Hallahan, Jane %A Mulholland, Kim %A Reid, Stewart %A Martin, Diana %D 2005 %J Vaccine %K Adolescent, Adult, Aged, Antibodies, B, Bacterial Bacterial, Child, Female, Humans, Infant, Infections, Male, Meningococcal Method, Middle Neisseria New Preschool, Safety Serogroup Vaccines, Zealand, meningitidis, {Double-Blind} %N 17-18 %P 2191--6 %R S0264-410X(05)00069-1 %T MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain %U http://www.ncbi.nlm.nih.gov/pubmed/15755593 %V 23 %X Clinical studies have been conducted in New Zealand evaluating the safety and immunogenicity of an outer membrane vesicle (OMV) vaccine, MeNZB, developed to control epidemic disease caused by group B meningococci, subtype P1.7b,4. MeNZB, administered in a three-dose regimen, was well tolerated and induced a seroresponse, defined as a four-fold rise (\textgreater or =titre 8) in serum bactericidal antibodies against the vaccine strain 4-6 weeks after the third vaccination, in 96\% (95\% confidence interval (CI): 79-100\%) of adults, 76\% (95\% CI: 72-80\%) of children, 75\% (95\% CI: 69-80\%) of toddlers and 74\% (95\% CI: 67-80\%) of infants receiving MeNZB. In conclusion, these findings suggest that MeNZB is safe and is likely to confer protection against systemic group B meningococcal disease caused by the epidemic strain.

@article{oster_menzb:_2005, abstract = {Clinical studies have been conducted in New Zealand evaluating the safety and immunogenicity of an outer membrane vesicle {(OMV)} vaccine, {MeNZB,} developed to control epidemic disease caused by group B meningococci, subtype P1.7b,4. {MeNZB,} administered in a three-dose regimen, was well tolerated and induced a seroresponse, defined as a four-fold rise ({\textgreater} or =titre 8) in serum bactericidal antibodies against the vaccine strain 4-6 weeks after the third vaccination, in 96\% (95\% confidence interval {(CI):} 79-100\%) of adults, 76\% (95\% {CI:} 72-80\%) of children, 75\% (95\% {CI:} 69-80\%) of toddlers and 74\% (95\% {CI:} 67-80\%) of infants receiving {MeNZB.} In conclusion, these findings suggest that {MeNZB} is safe and is likely to confer protection against systemic group B meningococcal disease caused by the epidemic strain.}, added-at = {2011-03-11T10:05:34.000+0100}, author = {Oster, Philipp and Lennon, Diana and {O'Hallahan}, Jane and Mulholland, Kim and Reid, Stewart and Martin, Diana}, biburl = {https://www.bibsonomy.org/bibtex/2bb463cbd7b96a6415c6377ce0c92ff5d/jelias}, doi = {S0264-410X(05)00069-1}, interhash = {9eaf73bf72593bbc2be154a7f51dde36}, intrahash = {bb463cbd7b96a6415c6377ce0c92ff5d}, issn = {{0264-410X}}, journal = {Vaccine}, keywords = {Adolescent, Adult, Aged, Antibodies, B, Bacterial Bacterial, Child, Female, Humans, Infant, Infections, Male, Meningococcal Method, Middle Neisseria New Preschool, Safety Serogroup Vaccines, Zealand, meningitidis, {Double-Blind}}, month = mar, note = {{PMID:} 15755593}, number = {17-18}, pages = {2191--6}, shorttitle = {{MeNZB}}, timestamp = {2011-03-11T10:05:52.000+0100}, title = {{MeNZB:} a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain}, url = {http://www.ncbi.nlm.nih.gov/pubmed/15755593}, volume = 23, year = 2005 }